SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Zonneveld Anton Jan van)
 

Sökning: WFRF:(Zonneveld Anton Jan van) > Cardiovascular Risk...

  • Bredewold, Obbo WLeiden Univ, Netherlands (författare)

Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients : A Randomized Clinical Trial

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • Elsevier,2023
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-498007
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-498007URI
  • https://doi.org/10.1016/j.xkme.2022.100574DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-193464URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:236593877URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • RATIONALE & OBJECTIVE: In kidney transplant recipients (KTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)-based regimens. Our objective was to compare the calculated CV risk between belatacept and CNI (predominantly tacrolimus) treatments using a validated model developed for KTRs.STUDY DESIGN: Prospective, randomized, open-label, parallel-group, investigator-initiated, international multicenter trial.SETTING & PARTICIPANTS: KTRs aged 18-80 years with a stable graft function (estimated glomerular filtration rate > 20 mL/min/1.73 m2), 3-60 months after transplantation, treated with tacrolimus or cyclosporine A, were eligible for inclusion.INTERVENTION: Continuation with a CNI-based regimen or switch to belatacept for 12 months.OUTCOMES: Comparison of the change in the estimated 7-year risk of major adverse CV events and all-cause mortality, changes in traditional markers of CV health, as well as measures of arterial stiffness.RESULTS: Among the 105 KTRs randomized, we found no differences between the treatment groups in the predicted risk for major adverse CV events or mortality. Diastolic blood pressure, measured both centrally by using a SphygmoCor device and peripherally, was lower after the belatacept treatment than after the CNI treatment. The mean changes in traditional cardiovascular (CV) risk factors, including kidney transplant function, were otherwise similar in both the treatment groups. The belatacept group had 4 acute rejection episodes; 2 were severe rejections, of which 1 led to graft loss.LIMITATIONS: The heterogeneous baseline estimated glomerular filtration rate and time from transplantation to trial enrollment in the participants. A limited study duration of 1 year.CONCLUSIONS: We found no effects on the calculated CV risk by switching to the belatacept treatment. Participants in the belatacept group had not only lower central and peripheral diastolic blood pressure but also a higher rejection rate.FUNDING: The trial has received a financial grant from Bristol-Myers Squibb.TRIAL REGISTRATION: EudraCT no. 2013-001178-20.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Chan, JoeAkershus Univ Hosp, Norway (författare)
  • Svensson, MyAalborg Univ Hosp, Denmark (författare)
  • Bruchfeld, AnnetteKarolinska Institutet,Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Karolinska Univ Hosp, Sweden(Swepub:liu)anbru14 (författare)
  • de Fijter, Johan WLeiden Univ, Netherlands (författare)
  • Furuland, HansUppsala universitet,Njurmedicin,Univ Hosp, Sweden(Swepub:uu)hansfl (författare)
  • Grinyo, Josep MUniv Barcelona, Spain (författare)
  • Hartmann, AndersOslo Univ Hosp, Norway (författare)
  • Holdaas, HallvardOslo Univ Hosp, Norway (författare)
  • Hellberg, OlofOrebro Univ, Sweden (författare)
  • Jardine, AlanUniv Glasgow, Scotland (författare)
  • Mjörnstedt, LarsSahlgrens Univ Hosp, Sweden (författare)
  • Skov, KarinAarhus Univ Hosp, Denmark (författare)
  • Smerud, Knut TSmerud Med Res Int AS, Norway (författare)
  • Soveri, IngaUppsala universitet,Njurmedicin,Univ Hosp, Sweden(Swepub:uu)insov254 (författare)
  • Sørensen, Søren SCopenhagen Univ Hosp, Denmark (författare)
  • Zonneveld, Anton-Jan vanLeiden Univ, Netherlands (författare)
  • Fellström, Bengt,1947-Uppsala universitet,Njurmedicin,Univ Hosp, Sweden(Swepub:uu)bengfell (författare)
  • Leiden Univ, NetherlandsAkershus Univ Hosp, Norway (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Kidney Medicine: Elsevier5:12590-0595

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy